search
Back to results

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

Primary Purpose

Myopia

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
omafilcon A
Spectacle
Sponsored by
Coopervision, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia

Eligibility Criteria

8 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Prior to being considered eligible to participate in this study, each subject MUST:

    1. Be between 8 and 12 years of age inclusive at the baseline examination.
    2. Have:

      1. read the Informed Assent,
      2. been given an explanation of the Informed Assent,
      3. indicated an understanding of the Informed Assent and
      4. signed the Informed Assent Form.
    3. Have their parent or legal guardian:

      1. read the Informed Consent,
      2. been given an explanation of the Informed Consent,
      3. indicated an understanding of the Informed Consent and
      4. signed the Informed Consent Form.
    4. Along with their parent or guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol.
    5. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study
    6. Agree to accept either the control or test lens as assigned by the randomisation scheme.
    7. Agree to wear the assigned contact lenses for the duration of the 2 year study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)
    8. Possess wearable and visually functional eyeglasses.
    9. Be in good general health, based on his/her and parent's/guardian's knowledge.
    10. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
    11. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline:

      1. Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D inclusive.
      2. Astigmatism: < -0.75 D
      3. Anisometropia: < 1.00D

Exclusion Criteria:

  • Subjects may not be considered eligible if ANY of the following apply:

    1. Subject has previously or recently worn soft or rigid gas permeable contact lenses, including orthokeratology lenses.
    2. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).
    3. Subject is currently or prior to this study has been an active participant in another clinical study.
    4. Parent / guardian or close relative is a member, of the office staff, including the investigator(s).
    5. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment.
    6. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at birth.
    7. Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents.
    8. Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state. Such as, but not limited to: long term use of nasal decongestants (for example, pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methylphenidate).
    9. A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
    10. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
    11. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
    12. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes.
    13. Any ocular, systemic or neuro-developmental conditions that could influence refractive development. Such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome, Stickler's syndrome, ocular albinism, retinopathy of prematurity.
    14. Keratoconus or an irregular cornea.
    15. Biomicroscope findings that would contraindicate contact lens wear including, but not limited to:

      1. corneal scars within the visual axis
      2. neovascularisation or ghost vessels > 1.5 mm in from the limbus
      3. Any active anterior segment ocular disease that would contraindicate contact lens wear.
      4. giant papillary conjunctivitis of Grade 2 or worse
      5. allergic or seasonal conjunctivitis (if the study investigator believes it could significantly interfere with maintaining the specified contact lens wearing schedule)
      6. clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures.
    16. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.
    17. Have pathological myopia To be eligible to begin the study, a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present.

Sites / Locations

  • Departamento de Óptica y Optometría de la Universidad Europea de Madrid

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

omafilcon A

Spectacle Group

Arm Description

Contact Lens Group

Prescription at Baseline

Outcomes

Primary Outcome Measures

Change in the spherical equivalent refractive error relative to baseline.
Change in axial length relative to baseline.
Measurement of corneal curvature (keratometry)relative to baseline.

Secondary Outcome Measures

Measurement of pupil diameter relative to baseline.

Full Information

First Posted
August 2, 2013
Last Updated
July 30, 2020
Sponsor
Coopervision, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01917110
Brief Title
Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.
Official Title
Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
September 13, 2013 (Actual)
Primary Completion Date
June 16, 2016 (Actual)
Study Completion Date
June 16, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coopervision, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.
Detailed Description
Subjects in two parallel groups were randomized and assigned to either the study contact lens (omafilcon a) or single vision spectacles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
79 (Actual)

8. Arms, Groups, and Interventions

Arm Title
omafilcon A
Arm Type
Experimental
Arm Description
Contact Lens Group
Arm Title
Spectacle Group
Arm Type
Active Comparator
Arm Description
Prescription at Baseline
Intervention Type
Device
Intervention Name(s)
omafilcon A
Intervention Type
Device
Intervention Name(s)
Spectacle
Primary Outcome Measure Information:
Title
Change in the spherical equivalent refractive error relative to baseline.
Time Frame
Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months
Title
Change in axial length relative to baseline.
Time Frame
Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months
Title
Measurement of corneal curvature (keratometry)relative to baseline.
Time Frame
Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months
Secondary Outcome Measure Information:
Title
Measurement of pupil diameter relative to baseline.
Time Frame
Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Prior to being considered eligible to participate in this study, each subject MUST: Be between 8 and 12 years of age inclusive at the baseline examination. Have: read the Informed Assent, been given an explanation of the Informed Assent, indicated an understanding of the Informed Assent and signed the Informed Assent Form. Have their parent or legal guardian: read the Informed Consent, been given an explanation of the Informed Consent, indicated an understanding of the Informed Consent and signed the Informed Consent Form. Along with their parent or guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study Agree to accept either the control or test lens as assigned by the randomisation scheme. Agree to wear the assigned contact lenses for the duration of the 2 year study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.) Possess wearable and visually functional eyeglasses. Be in good general health, based on his/her and parent's/guardian's knowledge. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline: Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D inclusive. Astigmatism: < -0.75 D Anisometropia: < 1.00D Exclusion Criteria: Subjects may not be considered eligible if ANY of the following apply: Subject has previously or recently worn soft or rigid gas permeable contact lenses, including orthokeratology lenses. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear). Subject is currently or prior to this study has been an active participant in another clinical study. Parent / guardian or close relative is a member, of the office staff, including the investigator(s). Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at birth. Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents. Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state. Such as, but not limited to: long term use of nasal decongestants (for example, pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methylphenidate). A known allergy to fluorescein, benoxinate, proparacaine or tropicamide. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes. Any ocular, systemic or neuro-developmental conditions that could influence refractive development. Such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome, Stickler's syndrome, ocular albinism, retinopathy of prematurity. Keratoconus or an irregular cornea. Biomicroscope findings that would contraindicate contact lens wear including, but not limited to: corneal scars within the visual axis neovascularisation or ghost vessels > 1.5 mm in from the limbus Any active anterior segment ocular disease that would contraindicate contact lens wear. giant papillary conjunctivitis of Grade 2 or worse allergic or seasonal conjunctivitis (if the study investigator believes it could significantly interfere with maintaining the specified contact lens wearing schedule) clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study. Have pathological myopia To be eligible to begin the study, a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cesar Villa Collar, OD PhD FAAO
Organizational Affiliation
Departamento de Optica y Optometria de la Universidad Europea de Madrid
Official's Role
Principal Investigator
Facility Information:
Facility Name
Departamento de Óptica y Optometría de la Universidad Europea de Madrid
City
Madrid
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
33648464
Citation
Lopes-Ferreira D, Ruiz-Pomeda A, Perez-Sanchez B, Queiros A, Villa-Collar C. Ocular and corneal aberrations changes in controlled randomized clinical trial MiSight(R) Assessment Study Spain (MASS). BMC Ophthalmol. 2021 Mar 1;21(1):112. doi: 10.1186/s12886-021-01865-y.
Results Reference
derived
PubMed Identifier
33460537
Citation
Ruiz-Pomeda A, Prieto-Garrido FL, Hernandez Verdejo JL, Villa-Collar C. Rebound Effect in the Misight Assessment Study Spain (Mass). Curr Eye Res. 2021 Aug;46(8):1223-1226. doi: 10.1080/02713683.2021.1878227. Epub 2021 Jan 24.
Results Reference
derived
PubMed Identifier
30196481
Citation
Ruiz-Pomeda A, Perez-Sanchez B, Canadas P, Prieto-Garrido FL, Gutierrez-Ortega R, Villa-Collar C. Binocular and accommodative function in the controlled randomized clinical trial MiSight(R) Assessment Study Spain (MASS). Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):207-215. doi: 10.1007/s00417-018-4115-5. Epub 2018 Sep 8.
Results Reference
derived
PubMed Identifier
29396662
Citation
Ruiz-Pomeda A, Perez-Sanchez B, Valls I, Prieto-Garrido FL, Gutierrez-Ortega R, Villa-Collar C. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):1011-1021. doi: 10.1007/s00417-018-3906-z. Epub 2018 Feb 3.
Results Reference
derived

Learn more about this trial

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

We'll reach out to this number within 24 hrs